174665-68-0

Upstream product

• 19798-81-3 2-Amino-6-bromopyridine 
• 10602-03-6 ethyl 4-ethynylbenzoate 
• 150969-54-3 ethyl 4-(trimethylsilylethynyl)benzoate 
• 51934-41-9 4-iodobenzoic acid ethyl ester 

Downstream Products

• 204452-37-9 Ethyl 4-[2-(2-Aminopyridine-6-yl)ethyl]benzoate 
• 204452-39-1 3-{4-[2-(6-aminopyridin-6-yl)ethyl]benzoylamino}-2(S)-4-iodobenzenesulfonylaminopropionic acid ethyl ester 
• 298692-95-2 3-[4-(2-aminopyridin-6-ylethyl)benzoylamino]-2(S)-benzenesulfonylaminopropionic acid tert-butyl ester 
• 204452-40-4 3-{4-[2-(2-aminopyridin-6-yl)ethyl]benzoylamino}-2(S)-4-iodobenzenesulfonylamino-propionic acid 
• 801239-56-5 3-{4-[2-(6-{2-[2-(3-tert-butoxycarbonylamino-propoxy)-ethoxy]-ethylamino}-pyridin-2-yl)-ethyl]-benzoylamino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid 
• 801239-97-4 4-[2-(6-{2-[2-(3-tert-butoxycarbonylamino-propoxy)-ethoxy]-ethylamino}-pyridin-2-yl)-ethyl]-benzoic acid 
• 298692-94-1 4-[2-(2-aminopyridin-6-yl)ethyl]benzoic acid 

Relevant academic research and scientific papers

Chemical adaptor immunotherapy: Design, synthesis, and evaluation of novel integrin-targeting devices

A series of β-diketone derivatives of RGD peptidomimetics that selectively bind to αvβ3 and αvβ5 integrins were synthesized and covalently docked to the reactive lysine residues of monoclonal aldolase antibody 38C2. The resulting targeting devices strongl

Nonpeptide α(v)β3 antagonists. 1. Transformation of a potent, integrin-selective α(IIb)β3 antagonist into a potent α(v)β3 antagonist

Modification of the potent fibrinogen receptor (α(IIb)β3) antagonist 1 generated compounds with high affinity for the vitronectin receptor α(v)β3. Sequential modification of the basic N-terminus of 1 led to the identification of the